Navigation Links
Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
Date:11/10/2008

ista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 diabetes. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure.

For more information, please visit the Company's Web site at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual resu
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Synvista Therapeutics Posts Letter to Stockholders on Web Site
2. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
3. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
4. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
5. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
6. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
9. Synvista Therapeutics to be Featured on Wallst.net
10. Synvista Therapeutics to Present at the BIO InvestorForum 2007
11. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... FRANCISCO, Calif. , June 29, 2015   ... diagnostics company pioneering the field of molecular cytology, today ... Area News Group,s prestigious Top Workplaces list for the ... Top Workplace winners based solely on an annual survey ... humbled and honored that the degree to which Veracyte ...
(Date:6/29/2015)... 29, 2015 Elsevier , ... products and services, today announced the highlights of its ... 2014 Journal Citation Reports® (JCR) published by Thomson Reuters, ... from 2013 to 2014, ahead of the aggregate across ... rank in 62 subject categories, up from 61 in ...
(Date:6/26/2015)... Kan. , June 26, 2015 /PRNewswire/ ... PETX ), a pet therapeutics company focused ... innovative biopharmaceutical products for companion animals, today ... effectiveness study of capromorelin (AT-002), the company,s ... Capromorelin is a small molecule that mimics ...
(Date:6/26/2015)... ... June 26, 2015 , ... Charm Sciences, ... Inspection, Packers and Stockyards Administration (GIPSA) awarded a five year contract to Charm ... grains utilizing Charm’s ROSA DONQ-FAST5 Test. This 5 minute quantitative test extracts DON ...
Breaking Biology Technology:Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2
... Dendreon Corporation (Nasdaq: DNDN ) management will host a conference call ... second quarter 2009 financial results. Access to the discussion may be obtained as ... 11:30 AM ET /8:30 AM PT, Date: ... (domestic) or +1-719-325-4873 (international), Webcast: www.dendreon.com (homepage and investor ...
... , , , PITTSBURGH, July 30 ... the three and six months ended June 30, 2009. , , ... Adjusted diluted EPS, which excludes the impact of certain purchase accounting items ... $0.65 for the three and six months ended June 30, 2009, compared to $0.20 ...
... a weakened strain of the malaria parasite that will be ... developed in collaboration with researchers from the US, Japan and ... Malaria kills more than one million people each year and ... of at least 35 million years of healthy, productive human ...
Cached Biology Technology:Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET 2Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 2Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 3Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 4Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 5Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 6Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 7Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 8Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 9Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 10Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 11Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 12Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 13Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 14Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 15Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 16Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 17Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 18First genetically engineered malaria vaccine to enter human trials 2
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards (FPC) raises ... it will amount to at least 340 MSEK to that ... rapid increase in market growth and orders received the revenue ... that revenue for 2015 will exceed 1,500 MSEK to an ... 2,200 MSEK. Due to receipt of orders of ...
(Date:6/11/2015)... June 11, 2015 Daon, a global ... that its IdentityX Mobile Authentication Platform v4.0 has ... Alliance is an industry consortium launched in 2013 ... simpler, stronger authentication.  In order to receive certification, ... rigorous series of tests that measure compliance and ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... protective delivery vehicle that shuttles friendly bacteria safely through ... boost for the probiotics industry. The new technology ... drugs and even increase calcium absorption, according to research ... at the University of York this week. The ...
... coli strain that hit Germany in May 2011 ... of collaboration across the scientific community should give insight ... the Society for General Microbiology,s Autumn Conference 2011. ... BGI, China. Their sequence was provided in draft form ...
... this math more evident than in vertebrates, which are programmed ... do not. Snakes, of course, have no digits, and birds ... handle on how these developmental changes are orchestrated in the ... Which digits are they: a thumb with index and middle ...
Cached Biology News:New polymer research could boost probiotics industry 2Crowd-sourcing the E. coli O104:H4 outbreak 2
... 8 micro-bore tubes to 1 outflow ... tips, Rapid (several millisecond) solution change ... prevention , Solid construction 360, 250 ... For mounting on any micromanipulator Available ...
... (BTI-TN-5B1-4) derived from Trichoplusia ni egg ... be capable of expressing significantly higher ... to other insect cells. High Five ... time as adherent cultures- Quick adaptation into ...
... Racks are ideal for storage and transport ... polypropylene racks withstand extreme temperatures, making them ... may also be autoclaved for use in ... side accommodates 0.5ml microcentrifuge tubes, the other ...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Biology Products: